GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProtoKinetix Inc (OTCPK:PKTX) » Definitions » EBIT

PKTX (ProtoKinetix) EBIT : $-0.37 Mil (TTM As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is ProtoKinetix EBIT?

ProtoKinetix's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-0.09 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.37 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ProtoKinetix's annualized ROC % for the quarter that ended in Sep. 2024 was -72.11%. ProtoKinetix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ProtoKinetix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -8.43%.


ProtoKinetix EBIT Historical Data

The historical data trend for ProtoKinetix's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProtoKinetix EBIT Chart

ProtoKinetix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.20 -7.64 -2.33 -1.91 -0.42

ProtoKinetix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.11 -0.09 -0.09 -0.09

Competitive Comparison of ProtoKinetix's EBIT

For the Biotechnology subindustry, ProtoKinetix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProtoKinetix's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProtoKinetix's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ProtoKinetix's EV-to-EBIT falls into.



ProtoKinetix EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProtoKinetix  (OTCPK:PKTX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ProtoKinetix's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-0.34 * ( 1 - 0% )/( (0.471 + 0.472)/ 2 )
=-0.34/0.4715
=-72.11 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

ProtoKinetix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.34/( ( (0 + max(-0.058, 0)) + (0 + max(-0.087, 0)) )/ 2 )
=-0.34/( ( 0 + 0 )/ 2 )
=-0.34/0
= %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.001) - (0.059 + 0 + 0)
=-0.058

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.001) - (0.088 + 0 + 0)
=-0.087

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ProtoKinetix's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-0.374/4.435
=-8.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProtoKinetix EBIT Related Terms

Thank you for viewing the detailed overview of ProtoKinetix's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


ProtoKinetix Business Description

Traded in Other Exchanges
N/A
Address
109 W Main Street, Dalton, OH, USA, 44618
ProtoKinetix Inc is a research and development stage biotechnology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins). The AFGP is a compound produced by fish, insects, reptiles, bacteria, and plants that enable survival in freezing temperatures. The company also develops AFGP applications which include regenerative medicine issues including harvesting, processing, storage, and transplanting cells, tissues, and organs and treatments for chronic inflammatory conditions and diseases caused by stress factors, including UV radiation, oxidation, and cryopreservation and hydrogen peroxide.
Executives
Clarence Edward Smith director, 10 percent owner, officer: President & CEO 1845 COUNTY ROAD #214, ST. AUGUSTINE FL 32084
Michael Richard Guzzetta officer: CFO 412 MULBERRY STREET, MARIETTA OH 45750
Lachlan Grant Young 10 percent owner 6438 ROSEBERY AVE., WEST VANCOUVER A1 V7W2C6
Edward P. Mcdonough director 1226 WASHINGTON AVENUE, PARKERSBURG WV 26101
Susan Marie Woodward officer: CFO 705 DUGAN ROAD, BELPRE OH 45714
Peter Krogh Jensen director 4656 HOSKINS ROAD, NORTH VANCOUVER A1 V7K 2R1
Ian Thomas Gregory director 2225 FOLKESTONE WAY, WEST VANCOUVER A1 V7S 2Y6
Ross Laurence Senior director, officer: CEO PH-3, 5688 DALHOUISE ROAD, VANCOUVER A1 V6T 1W4
Mark L Baum director, officer: President C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130

ProtoKinetix Headlines